BioCryst Pharmaceuticals, - Cash, Cash Equivalents, Restricted Cash And Investments $354 Million At June 30, 2026 - BCRX News | RalliesBioCryst Pharmaceuticals, - Cash, Cash Equivalents, Restricted Cash And Investments $354 Million At June 30, 2026
B
BCRX• BioCryst Pharmaceuticals reports Q2 EPS and FY sales outlook
- BioCryst Pharmaceuticals, Inc. reported Q2 EPS of USD 0.3.
- The company said FY sales outlook is USD 690-715 million.
- BioCryst Pharmaceuticals said cash, cash equivalents, restricted cash and investments were $354 million at June 30, 2026.
